Dutch-US MedTech Xeltis raises €20.5 million to advance artificial vessels and valves replaced by patients’ own tissue
Xeltis, a commercial-stage MedTech company based in the Netherlands and the USA, developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue, has raised an additional €20.5 million in new funding. This funding was secured from new and existing sharehol
<p>Xeltis, a commercial-stage MedTech company based in the Netherlands and the USA, developing artificial vessels and valves that are gradually replaced by patients’ own living healthy tissue, has raised an additional €20.5 million in new funding. This funding was secured from new and existing sharehol</p>